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Abstract: Recent advances in our understanding of the role of interleukin (IL)-6 in autoim-
munity and in particular rheumatoid arthritis (RA) have brought about important changes in 
the way we think about autoimmune diseases. Encouraging data from several phase III clinical 
trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval 
in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported 
outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be 
summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, 
adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials 
will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to 
describe the current understanding of the role of IL-6 in mediating the inflammatory response 
in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this 
agent in other autoimmune diseases.
Keywords: tocilizumab, rheumatoid arthritis, IL-6, methotrexate
Introduction
Rheumatoid arthritis (RA) is an autoimmune disease characterized by persistent 
synovitis and destruction of bone and cartilage in multiple joints. RA affects up to 
1% of the population world wide and is more common in women.1,2 Conventional 
disease-modifying antirheumatic drugs (DMARDs) treatment options for moderate 
to severe RA include corticosteroids, azathioprine, methotrexate and leflunomide.3–5 
Current Food and Drug Administration (FDA)-approved biologic therapies include 
the tumor necrosis factor (TNF) inhibitors infliximab, adalimumab, golimumab, 
certolizumab, and etanercept; interleukin (IL)-1 inhibitor anakinra; the selective 
modulator of T cell activation abatacept; and the chimeric auto CD20 B-cell deplet-
ing agent, rituximab.6
Tocilizumab is the first humanized IL-6 receptor-inhibiting monoclonal antibody. 
IL-6 is a cytokine that is involved in the inflammatory and immunologic responses 
characteristic of multiple autoimmune diseases. The levels of IL-6 and its soluble 
receptor (sIL-6ra) are elevated in many rheumatic diseases.7,8 and the overproduction 
of IL-6 is thought to play a role in the pathogenesis of RA.9 Encouraging data from 
several clinical trials have led to the approval of tocilizumab in Europe in combina-
tion with methotrexate (MTX) for the treatment of adult patients with moderate to 
severe active RA who has inadequate response from previous treatment with one or 
more disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor 
inhibitors (TNF). It is approved in Europe for use as monotherapy in patients who are Therapeutics and Clinical Risk Management 2010:6 144
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either intolerant of MTX or for whom continued treatment 
with MTX is contraindicated.10 Furthermore, tocilizumab has 
been used in case reports and case series for the treatment of 
Castleman’s disease and systemic-onset juvenile idiopathic 
arthritis. It is approved for these indications in Japan.
Efficacy measurements of RA agents used in clinical 
trials generally involve the American College of Rheuma-
tology 20%, 50% and 70% improvement criteria (ACR20, 
ACR50, and ACR70). ACR20 responses are defined as 
20% improvement in the tender and swollen joint counts 
as well as 20% improvement in three of the five other 
core set measures: swollen joint count, tender joint count, 
physician’s assessment of disease activity, patient’s assess-
ment of disease activity, patient’s assessment of pain, and 
patient’s assessment of physical function, and levels of an 
acute-phase reactant.11
Here we will review the current understanding of the role 
of IL-6 in mediating the inflammatory response characteristic 
of RA, as well as the role of tocilizumab in the treatment of 
RA, particularly its efficacy (using ACR criteria) and toler-
ability in patients with RA, as demonstrated in clinical trials. 
Finally, we will describe the evolving role of tocilizumab as a 
targeted therapy in autoimmune diseases other than RA.
RA pathogenesis
RA is a chronic inflammatory disease defined by articular 
inflammation which results in joint destruction.1 RA is 
thought to begin when the immune system acquires im-
munity to an unknown self antigen, and this anti-self 
immune response later diversifies and evolves into a chronic 
inflammatory process.12 This dysregulation of the immune 
system is evidenced by the presence of autoantibodies such 
as anti-cyclic citrullinated peptide and rheumatoid factor, 
both of which are present many years prior to the patient 
presenting with clinical symptoms.13,14 The pathogenesis 
of rheumatoid arthritis (RA) involves the release of pro-
inflammatory mediators, including IL-6, from infiltrating 
lymphocytes and monocytes in the synovium. IL-6 likely 
promotes and sustains inflammation in the synovium by 
several different mechanisms.
IL-6 is a pleiotropic cytokine that has a broad spectrum 
of biologic activities. IL-6 was originally identified as a   
B-cell differentiation factor and is involved in the develop-
ment of antibody-producing plasma B-cells. This is note-
worthy because as noted above RA is characterized by the 
formation of particular autoantibodies.
IL-6 acts upon neutrophils, which are important in the 
acute inflammatory response in the synovium. Specifically, 
IL-6 increases neutrophil adherence to fibroblasts and increases 
leukocyte recruitment causing inflammation.15,16 Infiltrating 
inflammatory cells such as monocytes and macrophages, as 
well as endothelial cells release IL-6, which contribute to 
neutrophil recruitment during acute inflammation in RA.17
Furthermore, IL-6 stimulates vascular endothelial cells, 
synovial fibroblasts and osteoclasts and may contribute to 
the joint destruction and osteoporosis associated with RA. 
IL-6 has been shown to increase osteoclasts recruitment in 
human and animal studies. Additionally, IL-6 can stimulate 
osteoclasts maturation and activation and synoviocyte prolif-
eration,18 suggesting a role in bone reabsorption and synovial 
pannus formation. A number of in vitro studies support the 
idea that IL-6 plays a role in osteoclastogenesis.19–23 Finally, 
IL-6 depletes proteoglycans, which are a major component of 
articular cartilage. Thus IL-6 may contribute to joint destruc-
tion by a variety of processes, and it is not surprising that the 
amount of IL-6 present in the synovial fluid of RA patients 
correlates well with local joint measures of chronic synovitis 
and the severity of joint destruction in RA.19
IL-6 is a major cytokine inducer of acute phase response 
proteins,20 and it is known to be an endogenous pyrogen.6 
Thus, it seems likely that IL-6 plays a role in the systemic 
and constitutional manifestations of RA.21,22 Finally, IL-6 
and CRP are both associated with increased cardiovascular 
risk.23,24 While this association does not prove causation, this 
point is of particular interest given the increased burden of 
atherosclerotic disease observed in RA patients as compared 
to controls matched for known cardiovascular risk factors. 
Interestingly, elevations in serum IL-6 are associated with 
increased mortality in patients presenting with acute coronary 
syndrome, again suggesting the possibility that IL-6 plays a 
causal role in atherosclerotic disease.25
IL-6 is frequently elevated in the synovial fluid and serum 
in patients with RA, and elevations correlate well with disease 
activity and joint destruction. The large numbers of potential 
mechanisms by which IL-6 may mediate the systemic and 
articular manifestations of RA make it a logical target for 
treatment of the disease.20–23
Tocilizumab
Tocilizumab is a humanized, anti-human (IL-6) receptor 
monoclonal antibody of the IgG1 subclass, which prevents 
IL-6 from binding to its receptor.26 Since it is humanized, it will 
most likely present lower risk of antibody production compared 
with murine or chimeric mouse-human antibodies.26
IL-6 signal transduction is mediated by membrane bound 
(mIL-6R) and soluble (SIL-6R) receptors. In cells expressing Therapeutics and Clinical Risk Management 2010:6 145
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IL-6R on their cell surface, IL-6 binds to mIL-6R, and by 
associating with the gp130 protein transmits a signal into the 
cells. In addition, IL-6 can form an association with sIL-6R 
and transmit a signal through gp130.27 Therefore, it is crucial 
to inhibit both mIL-6R and sIL-6R-mediated signaling to 
block IL-6 signaling.18 Tocilizumab is developed by grafting 
the complementarity determining regions of a mouse anti-
human IL-6 receptor antibody onto human IgG1.28 Tocili-
zumab competes for both the membrane-bound (mIL-6R) and 
soluble (sIL-6R) forms of human IL-6 receptor, effectively 
blocking IL-6-mediated signal transmission in cells.18
An analysis of the pharmacokinetic properties of intrave-
nous tocilizumab examined data obtained from 1793 patients 
with RA who were administered tocilizumab 4 or 8 mg/kg 
every 4 weeks for 24 weeks.11 The predicted steady-state area 
under the concentration-time curve (AUC) was 2.7 with 6.5 
increase in tocilizumab 8 mg/kg as compared to 4 mg/kg.11 
Tocilizumab has a long half-life that is non-linear and con-
centration-dependent, which allows for administration every 
4 weeks.26 Tocilizumab 8 mg/kg administered every 4 weeks 
intravenously over 1 hour, is the recommended dosage for 
adults with RA.11 Prior to initiating therapy with tocilizumab, 
patients should be screened for latent tuberculosis infections 
and any other active infection, as use is not recommended 
in this setting.11
Regular observation of hepatic functions, lipid profile, 
and neutrophil and platelet counts is advised.11 It is recom-
mended to discontinue the medication if any of the fol-
lowing occur: alanine aminotransferase (ALT) or aspartate 
aminotransferase (AST) 5 times upper limit of normal, 
absolute neutrophil count 0.5 or decreased platelet count 
(50 × 103/uL).11
Phase I clinical trials
A phase I trial reported by Choy et al was conducted to 
determine safety and efficacy of tocilizumab in 45 patients 
that were placed in four different single dosage cohorts of 
0.1, 1, 5, and 10 mg/kg tocilizumab therapy or placebo. The 
percentage of patients achieving an ACR20, ACR50, or 
ACR70 response, or those achieving a Disease Activity Score 
(DAS)28 of less than 2.6 was not significantly different for 
any of the studied cohorts except the 5 mg/kg tocilizumab-
treated group, in which 55.6% of patients achieved an ACR20 
response. Adverse events reported were considered mild or 
moderate, and most events were common to both the tocili-
zumab and placebo-treated groups.
A phase I/II open-label multicenter randomized double-
blind placebo-controlled clinical trial was conducted and 
reported by Nishimoto in 2004. One hundred sixty-two 
patients were placed in either the tocilizumab or placebo-
treated group. The tocilizumab-treated group received either 
4 or 8 mg/kg intravenously every 4 weeks. Thirty-one of 
the patients withdrew during the study. Interestingly, 25 of 
the patients who withdrew were members of the placebo 
group. Statistically significant differences were observed in 
this study, indicating that the ACR20, ACR50, ACR70, and 
DAS28 of less than 2.6 was achieved in a higher percentage 
of patients treated with tocilizumab than those treated with 
placebo.
Phase II clinical trials
CHARISMA (Chugai Humanized Anti-Human Recombi-
nant Interleukin-6 Monoclonal Antibody), a multicenter 
randomized double-blind placebo-controlled trial, evaluated 
the safety and efficacy of tocilizumab in 359 patients with 
active RA and inadequate response to methotrexate. Stable 
methotrexate dosing was required for at least 4 weeks prior 
to enrollment and continued throughout the trial. Patients 
were randomized to receive tocilizumab at 2, 4, or 8 mg/kg 
as monotherapy; tocilizumab in combination with methotrex-
ate; or methotrexate with placebo. An ACR20 response at 
week 16 was achieved by 61% and 63% of patients receiving 
monotherapy with 4 mg/kg and 8 mg/kg of tocilizumab, com-
pared with 41% of patients receiving placebo plus MTX (P 
 0.05) The ACR50 and ACR70 was significantly improved 
with combination therapy of 8 mg/kg of tocilizumab plus 
methotrexate as compared to placebo plus methotrexate.29
The 34 patients that withdrew from CHARISMA due to 
adverse events experienced symptoms that were considered 
to be of mild to moderate intensity. Approximately 25% 
of the total adverse events reported were considered to be 
tocilizumab treatment-related. Laboratory abnormalities 
noted such as increased ALT and AST levels were considered 
treatment-related because of their characteristic rise and fall 
between treatments. These laboratory abnormalities did not 
cause the discontinuation of treatment.29
Other tocilizumab-related laboratory abnormalities 
documented in the CHARISMA study included blood lipids. 
Non-fasting total cholesterol, HDL, and triglycerides rose at 
the start of tocilizumab treatment and then returned and were 
maintained throughout the treatment portion of the study. 
Subjects that had increased lipid levels were mostly those 
with higher levels at study initiation.29
In the initial blinded study of tocilizumab monotherapy 
conducted by Nishimoto in Japan, 143 of 163 patients 
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extension to determine the safety and efficacy of tocilizumab. 
STREAM is the first study evaluating the efficacy of long-
term tocilizumab monotherapy (5 years) for patients with 
RA with an inadequate response to initial DMARD therapy. 
Of the original 163 patients, 143 continued to receive 
tocilizumab 8 mg/kg plus oral prednisone (8.0 mg/day) or 
NSAIDs. At 5 years, 84%, 69.1% and 43.6% of the patients 
achieved ACR20, ACR50, and ACR70 improvement respec-
tively. After 5 years of tocilizumab treatment, 89% of patients 
were taking a lower dose of corticosteroids.26 In the STREAM 
study, there were 49 withdrawals were due to adverse events. 
These adverse events were of mild or moderate severity. Only 
1 of the 49 withdrawals from the STREAM study was due to 
inadequate response to tocilizumab, and the rate of serious 
infections was similar to that reported by studies of anti-TNF 
agents.26 Although CHARISMA and STREAM did not report 
any serious cardiovascular adverse events or increased risk 
of developing cardiovascular disorders, further studies will 
need to examine this potential given the increase in serum 
lipids commonly induced by tocilizumab.26,29
Phase III clinical trials
Results from the LITHE (TociLIzumab Safety and The 
Prevention of Structural Joint Damage) trial, a three-arm, 
randomized, double-blind, placebo-controlled study were 
presented at the 2009 American College of Rheumatology 
(ACR) meeting. Enrolled patients were given methotrex-
ate and were randomized to receive either tocilizumab 8 
mg/kg, tocilizumab 4 mg/kg, or placebo every four weeks. 
The main outcomes measured in the trial were the changes 
from baseline in Genant-modified Sharp score and the AUC 
in the Health Assessment Questionnaire Disability Index   
(HAQ-DI) after 52 weeks. ACR response rates also were 
measured. Tocilizumab significantly inhibited the progression 
of joint damage in patients with RA. Also, patients treated 
with tocilizumab 8 mg/kg plus methotrexate at 52 weeks, 
56%, 36%, and 20% achieved ACR20, ACR50 and ACR70 
respectively. No differences in the frequency of adverse 
events were found among the 3 treatment arms. The study 
included nearly 1200 patients from 137 sites in 15 countries, 
including the United States.30
SAMURAI (Study of Active Controlled Monotherapy 
Used for Rheumatoid Arthritis) was an open-label multi-
  center randomized placebo-controlled study. The radiographic 
benefit of tocilizumab monotherapy versus conventional 
DMARD therapy was the primary outcome assessed during 
this trial was measured through a blinded evaluation of radio-
graphs from 302 Japanese patients with active RA for 5 years 
or less. Radiographs of hands and forefeet were evaluated 
using the van der Heijde modified Sharp method. Patients 
were assigned to receive either tocilizumab monotherapy of 
8 mg/kg every 4 weeks or conventional DMARDs for 52 
weeks. In the primary efficacy analysis, the tocilizumab group 
showed significantly less radiographic disease progression 
than those patients treated with conventional DMARDs. At 
week 52, the proportion of patients achieving an ACR20, 
ACR50, and ACR70 response was 78%, 64%, and 44% 
respectively in the tocilizumab group, which was statisti-
cally superior compared to the proportions of responders in 
the DMARD group (34%, 13% and 6% ACR20, 50 and 70 
responses respectively).31
Most adverse events reported in the SAMURAI study 
were mild or moderate in severity, and the proportion of these 
mild to moderate adverse events in the tocilizumab-treated 
group was very similar to that observed in the DMARD 
group (89% for tocilizumab vs 82% for DMARD). The 
most common adverse events reported were nasopharyngitis, 
with a similar occurrence rate in both groups. Laboratory 
abnormalities were more common in the tocilizumab group 
(61% of subjects) as compared to the DMARD group (31% 
of subjects), with many of the excess tocilizumab events 
being related to total cholesterol, triglycerides, HDL and 
LDL.31 However, similar to the CHARISMA study, adverse 
cardiovascular events were not reported.29 Serious adverse 
events (AEs) occurred in similar proportions of patients in 
the tocilizumab (18%) and DMARD (14%) groups with 
7.6% and 4.1% of patients reporting a serious infection, 
respectively.31
SATORI (Study of Active-controlled Tocilizumab mono-
therapy for Rheumatoid arthritis patients with inadequate 
response to methotrexate) studied the clinical efficacy of 
tocilizumab monotherapy in 125 patients with RA with 
inadequate response to low dose methotrexate. Patients were 
assigned to receive either tocilizumab 8 mg/kg every 4 weeks 
plus methotrexate placebo (tocilizumab group) or a tocili-
zumab placebo plus methotrexate 8 mg/week for 24 weeks 
(control group). The tocilizumab group achieved 80% ACR20 
response compared to 25% in the control group at week 24, 
indicating superiority of tocilizumab treatment (P  0.001). 
The ACR50 response rate was 11% in the control group and 
49% in the tocilizumab group, and the ACR70 response rate 
was 6% and 29% in the control group and the tocilizumab 
groups respectively.32 Seven patients withdrew from the tocili-
zumab arm and 31 withdrew from the methotrexate groups. 
However, most of these withdrawals were not due to adverse 
events, and those adverse events reported were comparable Therapeutics and Clinical Risk Management 2010:6 147
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between both treatment arms. In this study, tocilizumab 
monotherapy for 24 weeks significantly improved signs and 
symptoms and was well tolerated in patients who had active 
RA despite receiving methotrexate.32
OPTION (Tocilizumab Pivotal Trial in methotrexate 
inadequate responders), the first published randomized 
double-blind placebo-controlled trial was designed to study 
tocilizumab efficacy on patients who also took a stable back-
ground dose of methotrexate. It involved 623 adult patients 
with moderate to severe RA split into three groups who 
received either tocilizumab 8 mg/kg, 4 mg/kg, or placebo 
in addition to stable pre-study methotrexate doses of 10 
to 25 mg/week (average dose ∼15 mg/week). The primary 
efficacy endpoint, the proportion of patients with an ACR20 
response, was achieved in 59% of patients in the tocilizumab 
8 mg/kg group and 48% in the 4 mg/kg group, as compared 
to 26% of the subjects who received placebo. ACR50 and 
ACR70 responses were also significantly more common 
in the tocilizumab 8 mg/kg group as compared to placebo 
(44% vs 11% and 22% vs 2% respectively). Patients taking 
either dose of tocilizumab also had greater improvements in 
HAQ-DI scoring of physical function from baseline, greater 
FACIT-Fatigue scores, and better improvements in physical 
and mental SF36 scores than those given a placebo. Despite 
the efficacy benefits provided by tocilizumab, more patients 
receiving tocilizumab than those given a placebo had at 
least one adverse event (69% in the 8 mg/kg group, 71% 
in the 4 mg/kg group, and 63% in the placebo group), with 
serious infections or infestations being the most commonly 
reported serious adverse event occurring in 6 patients in the 
8 mg/kg group, 3 in the 4 mg/kg group, and 2 in the placebo 
group. No increases in levels of total bilirubin or alkaline 
phosphatase levels were reported in OPTION; however tocili-
zumab treatment was temporarily stopped or discontinued 
in OPTION subjects that displayed extremely high ALT and 
AST levels.33
RADIATE (Rheumatoid arthritis study in Anti-TNF fail-
ures) involved 499 RA patients, and its basic study design 
was similar to that of OPTION. Patients were treated with a 
stable background dose of methotrexate of 10 to 25 mg/ week 
(average ∼16 mg/week), and were split into the same three 
treatment groups. However, the patient population was limited 
to those who were previously refractory to anti-TNF therapy. 
An ACR20 response, which was the primary efficacy endpoint 
of the study, was achieved in 50% of the tocilizumab 8 mg/kg 
group, as compared to 30% in the 4 mg/kg group and 10% 
in the placebo group. As in the OPTION study, ACR50 and 
ACR70 responses were significantly more common in the 
tocilizumab 8 mg/kg group (29% and 12% respectively) as 
compared to the placebo group (4% and 1% respectively).34 
Greater improvements in HAQ values from baseline were 
achieved by 8 mg/kg tocilizumab (P  0.001) and 4 mg/kg 
tocilizumab (P = 0.003) relative to placebo. Mild and moder-
ate cases of infection, gastrointestinal upset, rash, and head-
aches were frequently reported in both the tocilizumab-treated 
and placebo-control group in the RADIATE trial. Eighty-four 
percent and 87% of subjects experienced an adverse event 
in the 8 mg/kg and 4 mg/kg tocilizumab-treatment cohort 
respectively, which was similar to the 80% adverse event 
rate reported in the placebo-treated cohort. Five patients in 
the tocilizumab-treated group were diagnosed with Common 
Terminology Criteria for Adverse Events CTCAE grade 4 
neutropenia, which caused withdrawal from the study. It was 
discovered that one the patients had grade 4 neutropenia prior 
to enrollment and treatment in the study; however the other 
4 patients developed grade 4 neutropenia while on the study 
medication.34
TOWARD (Tocilizumab in combination with traditional 
DMARD therapy) is the largest multicenter randomized 
double-blind placebo-controlled study to date, involving 
1220 patients who were randomized in a 2:1 manner to 
receive either tocilizumab 8 mg/kg or placebo. Unlike the 
previous phase III trials, TOWARD was designed to study a 
more representative and diverse clinic population, as patients 
could be enrolled if they were taking any stable single or 
multiple agent conventional DMARD regimen, rather than 
just methotrexate. It did, however, exclude those who had 
had an inadequate response to anti-TNF therapy. Methotrex-
ate was the most common background DMARD (average 
dose ∼15 mg/week) and was used in approximately 76% of 
patients, followed by anti-malarials, sulfasalazine, and leflu-
nomide were used in approximately 20%, 13%, and 13% of 
patients respectively. Multiple DMARDs were used in 23% 
of patients. Efficacy results for tocilizumab were similar to 
that of previous studies, with an ACR20 response rate (the 
primary endpoint) of 61%, an ACR 50 of 38% and an ACR 
70 of 21%, all significantly increased as compared to placebo 
ACR20, ACR50 and ACR70 response rates of 25%, 9%, and 
3% respectively. Tocilizumab was also superior to placebo 
in eliciting DAS28 and EULAR responses.
The TOWARD study noted a similar large number of 
mild and moderate severity adverse events, and some type 
of adverse event was reported in 73% of the tocilizumab-
treated patients and 61% of the placebo-treated patients. 
Of the adverse events reported, less than 10% were serious 
and resulted in discontinuation of the trial, and the majority Therapeutics and Clinical Risk Management 2010:6 148
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of these serious events occurred in the tocilizumab-treated 
group. Neutropenia was a common adverse event in the 
  tocilizumab-treated group. The neutropenias reported 
were not clearly linked to any serious infections during 
the course of the trial, however as noted previously, the 
  neutropenia observed can be profound in some cases.
The most recent study of tocilizumab in RA, AMBITION 
(Actemra versus Methotrexate double-blind investigative 
trial in monotherapy), involved a total of 673 patients and 
was a double-blind, double-dummy, parallel-group study 
that sought to compare tocilizumab 8 mg/kg as monotherapy 
compared to escalating doses of methotrexate in patients 
who had not previously failed methotrexate or biologics. 
For those who received methotrexate, the starting dose was 
7.5 mg/week and was quickly escalated to 20 mg/week over 
an 8-week period. The primary endpoint, ACR20 response, 
was statistically superior in those who received tocilizumab 
monotherapy (70%) compared to those in the methotrexate 
group (52.5%). The proportion of patients who achieved a 
DAS28  2.6 was also significantly higher in the tocilizumab 
monotherapy group (34%) compared to the methotrexate 
group (12%). There was no significant difference in the 
incidence of serious adverse events with tocilizumab versus 
methotrexate (P = 0.50) but in the tocilizumab group, there 
was a higher incidence of reversible grade 3 neutropenia 
(3.1% vs 0.4%) and increased total cholesterol 240 mg/dL 
(13.2% vs 0.4%) relative to placebo, respectively.35,36
Summary of tocilizumab  
trials in RA
The above trial data demonstrate the therapeutic efficacy of 
tocilizumab in adult patients 18 with active moderate-to-
severe RA. Efficacy and safety results from the phase III 
trials are summarized in Table 1. The studies discussed in this 
review sought to assess the effects of treatment with intrave-
nous tocilizumab at doses of 2 to 8 mg/kg every 4 weeks.37 
ACR Response Criteria was used for efficacy analyses in all 
studies except the SAMURAI. Table 2 displays the adverse 
events and number of occurrences in published clinical trials 
of tocilizumab in RA. Those studies not included in the table 
did not have specific published adverse event data.
Overall, these trials demonstrated that tocilizumab was 
effective in RA treatment in a number of patient groups, 
including those with inadequate response to methotrexate 
or TNF inhibition. Tocilizumab in combination with metho-
trexate was quite effective in those who had failed anti-TNF 
therapy, and tocilizumab monotherapy was superior to 
methotrexate monotherapy in those who had not previously 
failed either drug. It is worth noting however, that only one 
large study (SAMURAI) lasting 52 weeks in 306 patients 
has examined the question of radiographic benefit from 
tocilizumab treatment. Radiographic progression occurred, 
but was retarded in those receiving tocilizumab monotherapy 
compared to conventional DMARDs in this randomized, 
blinded, but not placebo controlled study. Although direct 
comparisons between different studies is always fraught with 
difficulty due to different study designs and patient popula-
tions, the results seen in the large tocilizumab studies were 
similar to those obtained in recent RA trials of other biologic 
therapies, including rituximab in DANCER, ocrelizumab in 
ACTION, and certolizumab pegol in RAPID 2.31,35,38,39
Tocilizumab monotherapy was generally well tolerated 
overall. There were no specific infections related to tocili-
zumab therapy, including tuberculosis, which is a concern 
with anti-TNF therapy.29,31,33–36 However, it is possible that 
a fatal reactivation of Epstein-Barr virus infection which 
occurred in a patient during a Japanese study may be 
attributed to tocilizumab.37 Moderate increases in serum 
levels of total cholesterol, triglycerides and high density 
lipoprotein cholesterol are common in tocilizumab recipi-
ents, as are elevations in serum transaminases.29,33–37 For 
example, in the SAMURAI study, laboratory abnormalities 
were almost twice as common in the tocilizumab group as 
compared to the DMARD group (61% vs 31% of patients, 
respectively).31 As noted above, severe neutropenia has 
also been observed, and blood counts should be monitored 
regularly. Three malignancies were reported in SAMURAI 
in patients treated with tocilizumab.31 Additional analysis 
to compare the incidence of malignancies in Japanese RA 
patient will be required to assess the carcinogenic risk of 
IL-6 inhibition therapy.
Future directions
Tocilizumab has the potential of being used in various 
other autoimmune diseases which may be caused in part by 
dysregulation of IL-6. A case report described successful 
tocilizumab treatment of cardiomyopathy associated with 
Castleman disease, a rare lymphoproliferative disorder which 
is characterized by lymphadenopathy and inflammatory 
symptoms. IL-6 is thought to play a role in the pathogenesis 
of this disease, and the reversibility of cardiomyopathy fol-
lowing the use of tocilizumab in this case is intriguing.40
IL-6 may have prognostic significance in predicting car-
diovascular events in patients with angiographically proven 
and clinically stable CAD.41 Additionally, IL-6 was found to 
be an independent and useful biomarker of atherosclerosis of Therapeutics and Clinical Risk Management 2010:6 149
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Table 1 Summary of efficacy and safety results from phase III trials of tocilizumab
Trial N Treatment arms Main efficacy results Other efficacy results Safety outcomes Duration
LITHE30 1196 8 mg/kg tocilizumab, 
4 mg/kg tocilizumab,  
or placebo once 
every 4 weeks
Tocilizumab significantly 
inhibited progression of 
joint damage
With 8 mg/kg tocilizumab: 
ACR20: 56%, ACR50: 36% 
ACR70: 20%
No differences in AEs among 
treatment arms
2 years
SAMURAI31 306 8 mg/kg tocilizumab  
once every 4 weeks  
or DMARDs
Patients taking 
tocilizumab had 
significantly less 
radiographic disease 
progression than patients 
treated with DMARDs
Proportion of patients 
achieving an ACR20, 
ACR50, and ACR70 
response was statistically 
superior to the DMARD 
group and signs and 
  symptoms were more 
improved in patients 
  receiving tocilizumab
Similar proportions of mild 
to moderate AEs (89% vs 
82%) and serious AEs (18% 
vs 13%) for tocilizumab and 
DMARDs, respectively
52 weeks
SATORI32 125 8 mg/kg tocilizumab 
every 4 weeks plus  
MTX placebo 
(tocilizumab group)  
or tocilizumab placebo 
plus MTX 8 mg/week 
(control group)
25.0% and 80.3% of 
patients in the control 
and tocilizumabs groups 
achieved ACR20,  
  respectively
Tocilizumab significantly 
decreased serum VEGF 
levels
Incidences of AEs were 72% 
and 92% (serious AEs: 4.7 
and 6.6%; serious infections: 
1.6 and 3.3%) in control and 
tocilizumab groups, 
respectively; all serious AEs 
improved with adequate 
  treatment
24 weeks
OPTION33 623 8 mg/kg tocilizumab, 
4 mg/kg tocilizumab, or 
placebo every 4 weeks 
with MTX
More ACR20 responses 
in tocilizumab groups 
than in placebo group 
(odds ratio 4.0 [95% CI 
2.6–6.1], P  0.0001 for 
8 mg/kg vs placebo; and 
2.6 [1.7–3.9], P  0⋅0001 
for 4 mg/kg vs placebo)
Patients taking tocilizumab 
had greater improvements 
in HAQ-DI scoring of 
  physical function from 
  baseline, FACIT-Fatigue 
scores, and physical and 
mental SF36 scores than 
those given a placebo
More people in the 
tocilizumab group had at 
least 1 AE with the most 
  common serious AEs being 
  serious infections or 
infestations 6 patients in  
8 mg/kg group, 3 in the 4 mg/kg 
group, and 2 in the placebo 
group
24 weeks
RADIATE34 499 8 mg/kg tocilizumab, 
4 mg/kg tocilizumab, or 
placebo every 4 weeks 
with MTX
ACR20 was achieved in 
50% of the tocilizumab 
8 mg/kg group, as 
compared to 30% in the 
4 mg/kg group and 10% 
in the placebo 
group
Greater improvements in 
HAQ values from baseline 
achieved by 8 mg/kg 
tocilizumab (P  0.001) 
and 4 mg/kg tocilizumab 
(P = 0.003) relative to 
placebo; DAS28 and 
EULAR responses also 
were greater in tocilizumab 
groups
Mild and moderate cases of 
infection, gastrointestinal 
upset, rash, and headaches 
were frequently reported in 
both the tocilizumab-treated 
and placebo-control group
24 weeks
TOWARD35 1220 8 mg/kg tocilizumab or 
placebo every 4 weeks
Significantly more ACR20 
responses achieved in the 
tocilizumab plus DMARD 
group than in the control 
group (61% vs 25%;  
P  0.0001)
Tocilizumab was superior 
to placebo in DAS28 and 
EULAR responses
AEs reported in 73% of the 
tocilizumab-treated patients 
and 61% of the placebo- 
treated patients; majority of 
serious AEs occurred in the 
tocilizumab group
24 weeks
AMBITION36 673 Tocilizumab 8 mg/kg 
monotherapy vs  
escalating doses of 
MTX
ACR20 response, was 
statistically superior in 
those who received 
  tocilizumab monotherapy 
(70%) compared to those 
in the methotrexate 
group (52.5%)
DAS28  2.6 achieved by 
significantly more patients 
taking tocilizumab than 
MTX (34% vs 12%)
No differences in the 
incidence of AEs between 
  tocilizumab and placebo 
groups; most common AE 
was infection
24 weeks
Abbreviations: MTX, methotrexate; AEs, adverse events; DMARDs, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire; DAS28, Disease Activity 
Scale in 28 Joints; EULAR, European League Against Rheumatism Responses; VEGF, vascular endothelial growth factor.Therapeutics and Clinical Risk Management 2010:6 150
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the carotid artery in patients with moderate to high prevalence 
of CAD.42 IL-6 was evaluated in patients undergoing coro-
nary artery bypass grafting, and elevated preoperative IL-6 
levels were predictors of both early graft occlusion and late 
cardiovascular events after surgery.43 Furthermore, high 
plasma levels of IL-6 were an independent predictor of stroke 
in patients with atrial fibrillation.44
CAD is a major cause of death in patients with RA, and 
it is possible that IL-6 could contribute to the excess burden 
of cardiovascular disease in RA patients. While tocilizumab 
treatment was frequently associated with elevated total cho-
lesterol and LDL in the above studies, and improvement in 
HDL was also seen in some patients, and the ApoB/ApoA 
atherogenic index was generally unchanged. At this point in 
time, it is unclear what the impact of these changes will be 
upon overall cardiovascular risk in RA patients treated with 
tocilizumab.
Conclusion
IL-6 is a major inflammatory cytokine that contributes to 
the pathophysiology of RA, and IL-6 blockade is beneficial 
in experimental animal models of inflammatory arthritis. 
Clinical trial data have shown tocilizumab to be efficacious in 
moderate to severe rheumatoid patients failing DMARDS and 
anti-TNF agents. Given the promising results of tocilizumab 
in the treatment of RA, inhibition of IL-6 signaling with 
tocilizumab could be beneficial in other autoimmune diseases 
where IL-6 plays a role in the inflammatory cascade.
Cardiovascular disease is an important outcome in RA. 
The long term impact of tocilizumab on overall cardiovascu-
lar risk in RA patients remains unclear; however the influence 
of tocilizumab upon atherosclerotic disease is an important 
area for future exploration.
The toxicity associated with the long term use of tocili-
zumab is unknown. It is possible that adverse events could 
Table 2 Adverse events and number of occurrences in published clinical trials of tocilizumab in rheumatoid arthritis
Nishimoto37 Smolen45 
CHARISMA
Nishimoto31 SAMURAI Smolen33 OPTION
Tocilizumab 
8 mg/kg
Conventional 
DMARDS
Tocilizumab 
4 mg/kg
Tocilizumab 
8 mg/kg
Placebo
Total number 
of patients
109 359 157 145 212 206 129
Nasopharyngitis 23 56 47 11 12 10
Rash 24 17 6 13 11 3
Fever 6 3
Headache 5 29 11 3 15 14 9
Increased blood pressure 3 15 7 8 9
Infusion reaction 16 11
Pruritis 5 9 2
Sleepiness 3
Stomatitis 7 9 9 13
Upper respiratory infection 14 29 12 17 13
Cough 10 7 3 3
Dyspnea 6 3 3 0
Fatigue 9 3 6 5
Pharyngeal pain 6 2 4 3
Eczema 9 6
Nausea 9 2
Paronychia 9 1
Vertebral compression fracture 3 3
Any gastrointestinal disordera 37 21 18 63 68 55
Mouth ulcers 4 5 1
Peptic ulcers 1 0 2
Peripheral edema 5 4 2
Pyrexia         2 1 5
aAny gastrointestinal disorder includes abdominal discomfort, dyspepsia, vomiting, and diarrhea.Therapeutics and Clinical Risk Management 2010:6 151
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be prevented with proper patient selection in the future as we 
develop a more individualized approach to patient care. In 
the future, a team approach aiming to provide comprehensive 
clinical, translational, and economic research will allow us 
to serve our patients best.
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